[Treatment of organ transplant rejection with low doses of CsA and CTLA4-Ig].
OBJECTIVE
To study on treating organ transplant rejection with low doses of CsA and CTLA4-Ig.


METHODS
We set up a rat's cardiac transplant rejection model by Ono's way. The experimental rats were divided into four groups: group A: without any treatment; group B: intraperitoneal injection of CsA at 10 mg / (-1) / (-1) 1 - 7 days; after operation group C: intraperitoneal injection of 100 microgram CTLA4-Ig after 2nd operative day; group D: intraperitoneal injection of CsA 2 mg / (-1) / (-1) 1- 7 days after operation. 50 microgram CTLA4-Ig was given intraperitoneally on the 2nd day postoperation. The survival days of allograft, serum concentration of IL-2, and histological changes were tested.


RESULTS
The allograft survival time of the four groups was 7.2 +/- 0.7 (group A), 19.4 +/- 2.07 (group B), 31.6 +/- 1.8 (group C) and 24.6 +/- 2.07 (group D) respectively. There were significantly differences among the groups (P < 0.05). The survival time in group D was more prolonged than that in group B (P < 0.05). The concentration of IL-2 was significantly decreased after operation. Significant difference was observed between the control group and each treated group (P < 0.01). In group A, B, C and D allograft rejection was graded IV, II, I and I respectively.


CONCLUSIONS
CTLA4-Ig had a stronger immunosuppression than did CsA. The low doses of CsA and CTLA4-Ig had show a synergistic immunosuppression in allograft transplantation.
Qian
Yeben
Y
Department of General Surgery, First Affiliated Hospital Anhui Medical University, Anhui 230022, China.
Chen
Guihua
G
Huang
Jiefu
J
D000069594:Abatacept; D000818:Animals; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000627:therapeutic use*; D060908:CTLA-4 Antigen; D016572:Cyclosporine / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000188:drug therapy*; D018796:Immunoconjugates; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D014184:Transplantation, Homologous; D019737:Transplants
D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D000069594:Abatacept; D016572:Cyclosporine